New Delhi: Intas Pharmaceuticals has got approval from the Subject Expert Committee (SEC) functional under the Central Drug ...

Trastuzumab deruxtecan is a targeted drug used to treat certain types of cancer: breast cancer, gastric or gastroesophageal ...

Germany-headquartered CNS drug specialist Neuraxpharm today revealed that UK health technology assessor the National ...

Adding albumin to PN solutions can affect infusion flow rates and pump pressures, thereby compromising the appropriate delivery of PN solutions to patients. The theoretical risk of glycosylation ...

Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, today announces that the National Institute for ...

The Food and Drug Administration (FDA) has expanded the list of medicines exempted from value-added tax (VAT) to ensure ...

These new findings build on earlier research on light-linking solutions to improve infusion patient safety, which can be found in an article entitled “Untangling Infusion Confusion: A Comparative ...

Product review details, this product has received, on average, 4.70 out of 5 star rating.

2-Year U.S. Treasury Note Continuous Contract $103.063-0.023-0.02% 5-Year U.S. Treasury Note Continuous Contract $107.445-0.070-0.07% 10-Year U.S. Treasury Note Continuous Contract $110.875-0.125 ...

The Subject Expert Committee (SEC), under the Central Drugs Standard Control Organisation (CDSCO), has recommended approval of additional indication of US-based Bristol-Myers Squibb's anti-cancer drug ...